Skip to content
OpenCapital
Get started

Organon OGN Ontruzant — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%

Similar metrics at other companies

Incyte logo
INCYOPZELURA — Total revenues
$143.02M+20.5%
United Therapeutics logo
UTHROrenitram — Total revenues
$135.6M+12.3%
Amgen logo
AMGNOtezla — Total revenues
$431M-1.4%
Bristol-Myers Squibb logo
BMYOpdivo — Total Revenues
$2.15B-5.3%
Bristol-Myers Squibb logo
BMYOpdivo Qvantig — Total Revenues
$163M+1,711%
Eli Lilly logo
LLYVerzenio — Revenue
$1.3B+12.3%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's ontruzant — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's ontruzant — revenue?
Organon (OGN) reported ontruzant — revenue of $5M in Q1 2026.
How has Organon's ontruzant — revenue changed year-over-year?
Organon's ontruzant — revenue decreased by 72.2% year-over-year, from $18M to $5M.
What is the long-term trend for Organon's ontruzant — revenue?
Over 4 years (2021 to 2025), Organon's ontruzant — revenue has grown at a -5.7% compound annual growth rate (CAGR), from $125M to $99M.
What does ontruzant — revenue mean?
This metric represents the total gross sales generated from the Ontruzant biosimilar product line. It reflects the market demand and competitive positioning of this specific oncology therapeutic within the company's broader biosimilars portfolio. Tracking these revenues helps investors assess the product's lifecycle performance and its contribution to the company's overall pharmaceutical revenue stream.